← FDA DRUG APPROVALS

FDA ANDA · ANDA076554

SUMATRIPTAN

Sponsor: SUN PHARM INDS LTD

APPLICATION
ANDA076554
TYPE
ANDA
ORIGINAL APPROVAL
2009-08-10
LATEST ACTION
2020-07-20
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

SUMATRIPTAN SUCCINATEDiscontinued
SUMATRIPTAN SUCCINATE EQ 25MG BASE · TABLET · ORAL
SUMATRIPTAN SUCCINATEDiscontinued
SUMATRIPTAN SUCCINATE EQ 50MG BASE · TABLET · ORAL

Approval history

2020-07-20Labeling · Supplement 8 · standardAP
2015-11-23Labeling · Supplement 4 · standardAP
2012-08-10Labeling · Supplement 3 · standardAP
2011-02-18Labeling · Supplement 2AP
2009-08-10OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →